Clinical trials: Malignant Melanomas
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
It is a Phase 1 Multicenter Open-Label Multi-Cohort Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GNR-051 in Subjects with Advanced Solid Malignancies.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma
- Trial name
- NCT04544748
- Testing
- GNR-051
- Where
- 12 sites in Russia
- Volunteers
- 48 people
- Sponsor
- AO GENERIUM
Solid Tumours
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
This is an open-label, multi-center, dose-finding Phase 1 study that will enroll subjects at least 18 years old with unresectable or metastatic melanoma and BRAF V600 mutations.
- Trial name
- NCT01767454
- Testing
- Dabrafenib, Trametinib, Ipilimumab
- Where
- 7 sites in United States
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
Solid Tumors
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT03634982
- Testing
- RMC-4630
- Where
- 12 sites in United States
- Volunteers
- 133 people
- Sponsor
- Revolution Medicines, Inc.
Melanoma
A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
This study will assess the safety of Pegylated Interferon Alfa-2b (PEG-IFN) as an adjuvant treatment for melanoma.
- Trial name
- NCT02155322
- Testing
- Pegylated Interferon Alfa-2b
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Skin Cancer
DermaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of Skin Cancer
The purpose of this study is to evaluate the clinical validity of the proprietary DermaSensor Elastic Scattering Spectroscopy (ESS) device and classifier algorithm to support assessment of skin lesions suggestive of melanoma…
- Trial name
- DERM-SUCCESS (NCT06690086)
- Testing
- Lesion biopsy, DermaSensor Device Use
- Where
- United States
- Volunteers
- 1,028 people
- Sponsor
- DermaSensor, Inc.
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected).
- Trial name
- NCT03655756
- Testing
- IFx-Hu2.0
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- TuHURA Biosciences, Inc.
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Cancer, Melanoma
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
This was a single-arm, open-label, multi-center, Phase II study to evaluate dabrafenib and trametinib combination therapy in subjects with BRAF V600 mutation-positive, unresectable or metastatic Acral lentiginous or cutaneous…
- Trial name
- NCT02083354
- Testing
- Dabrafenib, Trametinib
- Where
- 13 sites in China, Hong Kong and 3 more
- Volunteers
- 77 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Melanoma
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma
This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.
- Trial name
- TUNINTIL-2 (NCT06961786)
- Testing
- TILT-123, TIL, Cyclophosphamide
- Where
- Denmark
- Volunteers
- 9 people
- Sponsor
- TILT Biotherapeutics Ltd.
Metastatic Melanoma
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo.
- Trial name
- NCT00724841
- Testing
- Obatoclax Mesylate, Temozolomide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Gemin X
Malignant Melanoma, Melanoma (Skin)
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
The purpose of this study is to find out if two new treatment cancer vaccines called SCIB1 and iSCIB1+ can be used safely when added to nivolumab (Opdivo) with ipilimumab (Yervoy), or SCIB1 with pembrolizumab (Keytruda).
- Conditions
- Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
- Trial name
- NCT04079166
- Testing
- SCIB1 or iSCIB1+ DNA vaccine
- Where
- 15 sites in United Kingdom
- Volunteers
- 173 people
- Sponsor
- Scancell Ltd
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
- Trial name
- NCT02743611
- Testing
- BPX-701, Rimiducid
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Bellicum Pharmaceuticals
Neoplasms
A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin.
- Trial name
- NCT00421811
- Testing
- ADH-1, melphalan
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Adherex Technologies, Inc.
Melanoma
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
The goals of this protocol are 1) to investigate the safety and tolerability of X4P-001 in combination with Keytruda® (pembrolizumab) in patients with advanced melanoma, and 2) to assess serial biopsies of melanoma tumor lesions…
- Trial name
- X4P-001-MELA (NCT02823405)
- Testing
- X4P-001, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- X4 Pharmaceuticals
Melanoma
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
The purpose of this study is to understand the characteristics of adults diagnosed with with clinically palpable stage III resectable melanoma, the associated treatment patterns for their disease, and outcomes associated with the…
- Trial name
- NCT07091695
- Testing
- Nivolumab + relatlimab, Nivolumab + ipilimumab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Malignant Melanoma
A Pilot Study of Pivanex in Patients With Malignant Melanoma
This pilot study will assess the safety and efficacy of Pivanex alone in patients with malignant melanoma who have relapsed after treatment with chemotherapy or Interleukin-2 (IL-2). Pivanex is an investigational agent.
- Trial name
- NCT00087477
- Testing
- Pivanex
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Titan Pharmaceuticals
Malignant Melanoma
A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
This study aims to evaluate safety and effect of combining an oncolytic adenovirus (delolimogene mupadenorepvec; LOAd703) with atezolizumab in patients with melanoma.
- Trial name
- NCT04123470
- Testing
- delolimogene mupadenorepvec, atezolizumab
- Where
- 3 sites in United States, Sweden
- Volunteers
- 24 people
- Sponsor
- Lokon Pharma AB
Nevus, Cicatrix
A Trial to Investigate Scar Improvement Efficacy of RN1001 (Avotermin) After Head and Neck Naevi Excision
This trial will investigate whether four doses of RN1001 (20ng, 50ng, 100ng and 200ng) are efficacious in preventing or reducing the resultant scar, as compared to placebo, when applied intradermally to wound margins following…
- Trial name
- NCT00656227
- Testing
- Avotermin
- Where
- United Kingdom
- Volunteers
- 239 people
- Sponsor
- Renovo
Unresectable or Metastatic Melanoma
A Study of ST-1898 for Unresectable or Metastatic Melanoma
ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT etc.
- Trial name
- NCT06359860
- Testing
- ST-1898 tablets
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Beijing Scitech-Mq Pharmaceuticals Limited
Melanoma
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
The purpose of this clinical research study is to evaluate the Best Overall Response Rate (BORR), (as per modified WHO criteria) in patients with previously treated melanoma-Stage III (unresectable) or Stage IV melanoma receiving…
- Trial name
- NCT00289627
- Testing
- ipilimumab (MDX-010, BMS-734016)
- Where
- 53 sites in United States, Austria and 8 more
- Volunteers
- 155 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.